Global Market Study on Clostridium Difficile Infection Treatment: Fidaxomicin Drug Type to Witness Rapid Adoption in the Near Future


Clostridium Difficile Infection Treatment  Market
  • Published On : Jan-2018 |
  • Pages : 184 Pages |
  • Format :

The provision of effective after sales services is the key focus area of players operating in the global clostridium difficile infection treatment market. Mergers and acquisitions, strategic collaborations and technology transfer agreements play a vital role in the global clostridium difficile infection treatment market. Key players are focusing on the need to efficiently meet the requirements of various end users in different facility centers, while ensuring customized services. Quality and positive outcome are of utmost importance to end use industries. Further, it has been noticed that acquisitions and collaborations are the key strategies adopted by global and local players for better service provision and to increase their consumer base in different geographies. Our new report captures such useful revelations of the global clostridium difficile infection treatment market.

Report structure that incorporates in-depth analysis, key recommendations and overall market viewpoint

The key part of this report is our analysis and recommendations on the global clostridium difficile infection treatment market. The report takes an overview of the global clostridium difficile infection treatment market and also underlines factors influencing the growth of the global clostridium difficile infection treatment market. We have also provided key strategic recommendations for both existing and new players in the market to emerge sustainably profitable. The report covers the competitive landscape that provides a dashboard view of companies that manufacture and provide services in the global clostridium difficile infection treatment market. The report contains company profiles of some of the key players and a strategic overview of mergers and acquisitions along with companies’ expansion plans across regions.

Market Segmentation

By Drug Type

  • Metronidazole
  • Vancomycin
  • Fidaxomicin

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Research Methodology

Our research methodology incorporates both primary and secondary research to collect the relevant market data. We have analyzed the market by considering the revenue through extensive primary research to understand the adoption patterns, historic trends, and challenges faced by the medical staff, the required treatment developments, and most preferred products. Key opinion leaders have been considered for primary research including experienced healthcare professionals in various healthcare facilities across different countries. These estimates have further been validated with product manufacturers, distributors, and suppliers. Extensive secondary research has been carried out to understand the treatment rate, adoption rate, regulatory scenarios, average selling price and reimbursement scenario by referring to published scientific literature from various databases such as the WHO, PubMed, Springer, and Wiley among many others. We have also analyzed the various companies’ annual reports, investor presentations, SEC filings, 10k reports and press releases to fetch substantial information about the market size, trends, opportunities, drivers and restraints as well as to analyze key players.

While estimating the market forecast, our team of expert analysts have also taken into consideration the various macro-economic indicators such as clostridium difficile infection treatment market outlook, gross domestic product and other pointers to arrive at the indicated market numbers. Top-down approach has been used to counter-validate the reached numbers in the global clostridium difficile infection treatment market, while bottom-up approach has been used to assess market numbers in the global clostridium difficile infection treatment market. Weighted average selling price is considered to estimate the market size of various drugs mentioned in the scope of the study. The country price is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard.

Overview of the global clostridium difficile infection treatment market

Clostridium difficile infection treatment market is a mature market and the introduction of new class drugs is a key characteristic of this market. According to our expert team of analysts, there are very less approved drugs for the treatment of clostridium difficile infections and typically, off-label drugs are used frequently to cure these infections. Key players in the global market are focusing on strengthening their position by acquiring small but established manufacturers of drugs for clostridium difficile infection treatment and are developing manufacturing capabilities to achieve economies of scale. A new anti-body drug has been recently approved that is expected to be beneficial in effecting a cure. As this is the most common hospital acquired infection, the number of patients are expected to increase in various hospitals across the globe. 

Increased use of antimicrobial drugs is one of the major factors leading to an unprecedented growth of the global market for clostridium difficile infection treatment

Clostridium difficile infection treatment usually occurs when people have taken antibiotics for a long period of time that change the normal colon bacteria allowing the clostridium difficile bacteria to grow and produce its toxins. High CDI risk antibiotics are clindamycin, cephalosporins, and quinolones including ciprofloxacin and levofloxacin. Increasing use of these antibiotics and antimicrobials is driving the incidence of clostridium difficile infection and is likely to drive the global clostridium difficile infection treatment market over the forecast period.

Newly introduced drugs are also likely to fuel revenue growth of the market. A vast majority of companies have started working on new clostridium difficile infection antibiotics to treat diarrhea that is caused due to excessive use of antibiotics. A large number of new clostridium difficile infection antibiotics are in the pipeline of big pharmaceutical companies. Several companies operating in the global market are evaluating combination therapies for pre-approved drugs including fidaxomycin and vancomycin, which are in the late stages of development. Expansion of indication of these drugs for clostridium difficile infection would further boost the adoption of these drugs across the globe.

Clostridium difficile is one of the most common hospital acquired infections and in the last decade, there has been a notable increase in the incidence of clostridium difficile infection as well as the severity of the infection owing to recurrence and antibiotic resistance. Disproportionately higher incidence is seen in patients undergoing a long-term antibiotic treatment such as in patients with diseases like COPD and urinary tract infection. A rising prevalence of these diseases would subsequently accelerate the growth of the global clostridium difficile infection treatment market.

clostridium difficile infection treatment market

Vancomycin drug type is anticipated to witness steady growth during the forecast period  

Use of fidaxomicin, vancomycin and metronidazole by hospital pharmacies and mail order pharmacies is emerging as a prominent trend and is expected to largely contribute towards global market revenue growth. Fidaxomicin is expected to be the most lucrative among all drug types in the global clostridium difficile infection treatment market, with an attractiveness index of 1.02.

Preference for alternative treatment options over antibiotics is likely to hamper the growth of the global clostridium difficile infection treatment market

Launch of antibody drugs for the treatment of clostridium difficile infection and prevention of recurrent clostridium difficile infection has shifted focus from antibiotics to newly approved classes of drugs. A new class of drugs called microbiome therapeutics is being developed for the treatment of clostridium difficile infections and many leading biopharmaceutical companies are actively working on it. This new class of drugs is expected to create a tough competition for conventional antibiotic treatments of clostridium difficile infections.

Company Profiles 

  • Merck & Co.,Inc.
  • Baxter International Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • Novartis AG
  • Astellas Pharma
  • Eli Lilly and Company
  • AstraZeneca Plc.
  • Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
  • Mylan
  • Others.
Back To Top